Adaptive Biotechnologies (ADPT) Tops Q2 EPS by 2c; Offers FY23 Revenue Guidance
Tweet
Share
E-mailGet Alerts ADPT Hot Sheet
Price: $28.55 +3.18%
Revenue Growth %: -23.8%
Financial Fact:
Net income (loss) (in Dollars per share): -5.69
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: -23.8%
Financial Fact:
Net income (loss) (in Dollars per share): -5.69
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Adaptive Biotechnologies (NASDAQ: ADPT) reported Q2 EPS of ($0.33), $0.02 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $48.9 million versus the consensus estimate of $44.87 million.
GUIDANCE:
Adaptive Biotechnologies sees FY2023 revenue of $205-215 million, versus the consensus of $207.2 million.
For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s said to plan value strategy overhaul to revive US sales growth
- Vera Bradley (VRA) Tops Q2 EPS by 10c ; Offers Guidance
- Yeti outlines growth targets and financial framework through 2030
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
